2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% – bringing potential reach to over 23 million patients across these initiatives Enhanced target for full carbon neu…
September is Blood Cancer Awareness Month. Get to know the stories of people living with, or advocating for those impacted by blood cancers and blood disorders. People who, in their own bold way, challenge the status quo – for themselves and those arou…
Land ho! Now what?Without a map or the notion of a GPS, ancient explorers ventured into unfamiliar territory searching for a place to settle. Cliffs, steep mountains and impassable rivers thwarted their efforts as time ticked on and supplies dwindled.D…
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 were on inclisiran) 1 New post-hoc analysis demonstrates…
Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumabSeven of ten patients discontinued eculizumab and remained on LNP023 as monotherapy, retaining hemoglobin (Hb) level…
Human health is inextricably linked to planetary health. As the impacts of climate change are being experienced around the globe, the impacts on global health are becoming more and more clear.Heat events and …
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs. bosutinib in patients previously treated with two or more tyrosine-kinase inhibitors (TKIs)1 Despit…
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanomaTafinlar + Mekinist remains an effective treatment option based on previously reported large, Phase III clinical trials1,2 Spartalizumab developm…
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple sclerosis (RMS)1 Approval based on two Phase III ASCLEPIOS s…
Basel, August 17, 2020 — Novartis welcomes the decision by the US District Court for the District of Delaware to uphold the validity of the Gilenya® (fingolimod) dosage regimen patent, as our intellectual property reflects the innovation and investment…